Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,372
  • Shares Outstanding, K 20,938
  • Annual Sales, $ 1,310 K
  • Annual Income, $ -17,050 K
  • 60-Month Beta 0.05
  • Price/Sales 95.07
  • Price/Cash Flow N/A
  • Price/Book 3.72
Trade LGVN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.67 +4.76%
on 06/30/22
8.79 -32.46%
on 06/03/22
-1.91 (-24.33%)
since 06/01/22
3-Month
5.67 +4.76%
on 06/30/22
15.49 -61.65%
on 04/05/22
-9.67 (-61.95%)
since 04/01/22
52-Week
2.84 +109.15%
on 11/17/21
45.00 -86.80%
on 11/24/21
-2.34 (-28.26%)
since 07/01/21

Most Recent Stories

More News
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Conference call scheduled for 8:30 a.m. ET today...

LGVN : 5.94 (+0.17%)
Longeveron Announces CEO Transition

-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide...

LGVN : 5.94 (+0.17%)
Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022

Live conference call at 8:30 a.m. EST...

LGVN : 5.94 (+0.17%)
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference

April events to highlight Longeveron’s commitment to developing cell therapeutics for chronic aging related diseases....

LGVN : 5.94 (+0.17%)
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...

LGVN : 5.94 (+0.17%)
SNY : 51.01 (+1.96%)
BMY : 76.84 (-0.21%)
TAK : 14.09 (+0.36%)
JNJ : 179.52 (+1.13%)
Recession Fears are Creating a Golden Opportunity for Biotech Stocks

It's worth taking the effort to learn how to invest in biotechs

LGVN : 5.94 (+0.17%)
AZN : 65.95 (-0.18%)
TCON : 1.9800 (-1.00%)
RIOT : 4.24 (+1.19%)
BIIB : 210.63 (+3.28%)
Is NIO Stock a Buy? What the Bulls and Bears Are Saying.

Today's dip may be a good time to buy NIO shares

LGVN : 5.94 (+0.17%)
NIO : 21.36 (-1.66%)
DWAC : 24.20 (+0.17%)
AMD : 73.67 (-3.66%)
Alzheimer’s News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?

Clinical trial data is helping out LGVN stock today

LGVN : 5.94 (+0.17%)
FUTU : 52.75 (+1.03%)
AMC : 13.53 (-0.15%)
AMD : 73.67 (-3.66%)
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...

MSB.AX : 0.680 (+11.48%)
LGVN : 5.94 (+0.17%)
MESO : 2.45 (+10.36%)
SAVA : 26.51 (-5.73%)
DNLI : 31.24 (+6.15%)
ALEC : 11.02 (+8.46%)
5 Cheap Energy Stocks Riding Oil Higher

Energy stocks are all the rage, but which ones are the best investments?

LGVN : 5.94 (+0.17%)
BRPM : 9.96 (unch)
ARBK : 4.01 (+6.65%)
NVAX : 57.15 (+11.12%)
ENSV : 1.9700 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 6.29
2nd Resistance Point 6.13
1st Resistance Point 6.03
Last Price 5.94
1st Support Level 5.77
2nd Support Level 5.61
3rd Support Level 5.51

See More

52-Week High 45.00
Fibonacci 61.8% 28.89
Fibonacci 50% 23.92
Fibonacci 38.2% 18.95
Last Price 5.94
52-Week Low 2.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar